Last reviewed · How we verify
NCT03669926: To-Be 2
The Tomosynthesis Trial in Bergen - Part 2
NA trial testing Digital Breast Tomosynthesis+synthetic mammography in Breast Neoplasms in 31,082 participants. Completed in 30 June 2023.
30 June 2020
Quick facts
| Lead sponsor | Norwegian Institute of Public Health |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 31,082 |
| Start date | 1 January 2018 |
| Primary completion | 30 June 2020 |
| Estimated completion | 30 June 2023 |
| Sites | 1 location across Norway |
Drugs / interventions tested
- Digital Breast Tomosynthesis+synthetic mammography
Conditions studied
- Breast Neoplasms — all drugs for Breast Neoplasms →
Sponsor
Norwegian Institute of Public Health
Who can join
Adults 48 to 71, female only, with Breast Neoplasms. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of the study is to compare early performance measures and economic aspects of organized breast cancer screening for women screened using digital breast tomosynthesis+synthetic mammography (DBT+SM) to women with a prior DBT+SM or digital mammography (DM) from To-Be 1 (NCT02835625).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Digital breast tomosynthesis in mammographic screening: false negative cancer cases in the To-Be 1 trial.
Moshina N, Gräwingholt A, Lång K, Mann R, et al · · 2024 · cited 1× · PMID 38332187 · DOI 10.1186/s13244-023-01604-5
Verify or expand the search:
- PubMed search for NCT03669926
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Breast Neoplasms
Currently open trials in the same condition.
- NCT07214532 — Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer · NA · recruiting
- NCT07500428 — Construction of a Benchmark for Breast Ultrasound AI Interpretation and Performance Evaluation of Multimodal AI Models · recruiting
- NCT07581834 — Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multic · Phase 2 · recruiting
- NCT07222215 — PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA) · Phase 2 · recruiting
- NCT07465393 — Facility-Based Multi-Modal Rehab vs. Home-Based Resistance Exercise for Quality of Life in Breast Cancer Survivors · NA · recruiting
Other Norwegian Institute of Public Health trials
Trials by the same sponsor.
- NCT07442318 — Enabling Environments for Non-communicable Disease Risk Reduction in Ethiopia · NA · not yet recruiting
- NCT07135115 — Targeting Lifestyle to Improve Colorectal Cancer Screening · NA · not yet recruiting
- NCT07355569 — The Effect on Attendance of an SMS Notification Prior to a Scheduled Screening Appointment in BreastScreen Norway · NA · completed
- NCT06324409 — ImmigrantScreen Telephone Reminder Trial in Colorectal Cancer Screening · NA · completed
- NCT06374316 — Air Purifiers in Classrooms for Infection Control - a Pilot Study · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03669926 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Norwegian Institute of Public Health
- Last refreshed: 28 August 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03669926.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing